A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma is a research paper published in Neuro-Oncology (2025). On theSindex it has a DataRank of 0.394. It has been cited 9 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0.0490
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
NCI NIH HHS
Grant: UM1 CA137443
NCI NIH HHS
Grant: U24 CA224285
NCI NIH HHS
Grant: U24 CA224309
NCI NIH HHS
Grant: U24 CA224316
National Cancer Institute
MeSH Terms
Keywords